Working… Menu

Verapamil and Catamenial Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00559169
Recruitment Status : Withdrawn (protocol changed and a new study using verapamil in epilepsy will be started in the near future)
First Posted : November 16, 2007
Last Update Posted : April 8, 2010
Information provided by:
University Health Network, Toronto

Brief Summary:
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

Condition or disease Intervention/treatment Phase
Catamenial Epilepsy Drug: verapamil hyrochloride Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Verapamil in Refractory Catamenial Epilepsy
Study Start Date : February 2009
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures

Intervention Details:
  • Drug: verapamil hyrochloride
    80 mg daily by mouth, 5 days prior to menses for 3 months
    Other Name: apo-verap, isoptin

Primary Outcome Measures :
  1. the percent reduction in seizure frequency [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • females
  • at least 2 seizures per month
  • more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
  • patient of the Toronto Western Hospital Epilepsy Clinic

Exclusion Criteria:

  • cardiovascular history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00559169

Layout table for location information
Canada, Ontario
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Sponsors and Collaborators
University Health Network, Toronto
Layout table for investigator information
Principal Investigator: Danielle Andrade, MD College of Physicians and Surgeons of Ontario
Layout table for additonal information Identifier: NCT00559169    
Other Study ID Numbers: UHN-TWH-VER-001
First Posted: November 16, 2007    Key Record Dates
Last Update Posted: April 8, 2010
Last Verified: November 2007
Keywords provided by University Health Network, Toronto:
menstrual cycle
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents